CoChat

Baclofen for alcohol withdrawal

Open access
Liu, Jia, Wang, Lu-Ning · 2017 · Cochrane Database of Systematic Reviews
Cited by 102

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Alcohol withdrawal syndrome (AWS) is a distressing and life-threatening condition that usually affects people who are alcohol dependent when they discontinue or decrease their alcohol consumption. Baclofen shows potential for rapidly reducing symptoms of severe AWS in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane Review first published in 2011 and last updated in 2017. OBJECTIVES: To assess the efficacy and safety of baclofen for people with AWS. SEARCH METHODS: We updated our searches of the following databases to June 2019: the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, PubMed, Embase, and CINAHL. We also searched registers of ongoing trials. We handsearched the references quoted in the identified trials, and sought information from researchers, pharmaceutical companies, and relevant trial authors about unpublished or uncompleted trials. We placed no restrictions on language. SELECTION CRITERIA: We included all randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for people with AWS. We excluded uncontrolled, non-randomised, or quasi-randomised trials. We included both parallel group and cross-over studies. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included four RCTs with 189 randomised participants (one RCT new for this update). None of the included studies reported the primary outcomes of alcohol withdrawal seizures, alcohol withdrawal delirium, or craving. For the comparison of baclofen and placebo (1 study, 31 participants), there was no evidence of a difference in Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) scores in eight-hour periods from days one to five (very low-quality evidence). For the comparison of baclofen and diazepam (2 studies, 85 participants), there was no evidence of a difference in change from baseline to days 10 to 15 on CIWA-Ar scores (very low-quality evidence, meta-analysis was not performed due to insufficient data). In one study (37 participants), there was no evidence of a difference in participants with at least one adverse event (risk difference (RD) 0.00, 95% confidence interval (CI) -0.10 to 0.10; very low-quality evidence), dropouts (RD 0.00, 95% CI -0.10 to 0.10; very low-quality evidence), and dropouts due to adverse events (RD 0.00, 95% CI -0.10 to 0.10; very low-quality evidence). For the comparison of baclofen and chlordiazepoxide (1 study, 60 participants), there was no evidence of a difference in difference from baseline to nine-day decremental fixed-dose intervention: CIWA-Ar scores (mean difference (MD) 1.00, 95% CI 0.70 to 1.30; very low-quality evidence), global improvement (MD 0.10, 95% CI -0.03 to 0.23; very low-quality evidence), 14/60 participants with adverse events (RD 2.50, 95% CI 0.88 to 7.10; very low-quality of evidence), dropouts (RD 0.00, 95% CI -0.06 to 0.06; very low-quality evidence), and dropouts due to adverse events (RD 0.00, 95% CI -0.06 to 0.06; very low-quality evidence). None of the RCTs provided information on random sequence generation or allocation concealment, therefore, we assessed them at unclear risk of bias. Two RCTs were not of double-blind design and had a high risk of bias in blinding (Addolorato 2006; Girish 2016). One RCT had more than 5% dropouts with high risk of attrition bias (Lyon 2011). We could not assess reporting bias as none of the prepublished protocols were available. AUTHORS' CONCLUSIONS: No conclusions can be drawn about the efficacy and safety of baclofen for the management of alcohol withdrawal because we found insufficient and very low-quality evidence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd008502.pub5

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 52

  1. Girish, 2016, A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome, Biomedical Journal, 39, 72, 10.1016/j.bj.2015.09.002 · DOI · Paper page
  2. Lyon, 2011, Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial, Journal of Hospital Medicine, 6, 469, 10.1002/jhm.928 · DOI · Paper page
  3. Addolorato, 2002, Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomised controlled study, Alcohol and Alcoholism (Oxford, Oxfordshire), 37, 504, 10.1093/alcalc/37.5.504 · DOI · Paper page
  4. Addolorato, 2007, Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study, Lancet, 370, 1915, 10.1016/S0140-6736(07)61814-5 · DOI · Paper page
  5. Addolorato, 2011, Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial, Alcohol and Alcoholism (Oxford, Oxfordshire), 46, 312, 10.1093/alcalc/agr017 · DOI · Paper page
  6. Beraha, 2016, Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial, European Neuropsychopharmacology, 26, 1950, 10.1016/j.euroneuro.2016.10.006 · DOI
  7. Farokhnia, 2015, Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial, Neuropsychopharmacology, 40, 1560, 10.1038/npp.2015.29 · DOI
  8. Franchitto, 2014, Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series, Alcohol and Alcoholism (Oxford, Oxfordshire), 49, 79, 10.1093/alcalc/agt169 · DOI · Paper page
  9. Garbutt, 2007, Baclofen for alcoholism, Lancet, 370, 1884, 10.1016/S0140-6736(07)61789-9 · DOI
  10. Garbutt, 2010, Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial, Alcoholism, Clinical and Experimental Research, 34, 1849, 10.1111/j.1530-0277.2010.01273.x · DOI · Paper page
  11. Geisel, 2016, Serum levels of brain-derived neurotrophic factor in alcohol-dependent patients receiving high-dose baclofen, Psychiatry Research, 240, 177, 10.1016/j.psychres.2016.04.007 · DOI
  12. Hauser, 2017, The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized clinical trial, Addiction, 112, 1173, 10.1111/add.13787 · DOI · Paper page
  13. Imbert, 2015, Anticraving effect of baclofen in alcohol- dependent patients, Alcoholism, Clinical and Experimental Research, 39, 1602, 10.1111/acer.12823 · DOI
  14. Krupitsky, 1993, Baclofen administration for the treatment of affective disorders in alcoholic patients, Drug and Alcohol Dependence, 33, 157, 10.1016/0376-8716(93)90057-W · DOI
  15. Krupitsky, 1995, Effect of pharmacotherapy of affective disorders on the psycho-semantics of alcoholic patients, Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia i Meditsinskoi Promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe Obshchestvo Nevrologov [i] Vserossiiskoe Obshchestvo Psikhiatrov, 95, 67
  16. Krupitsky, 2015, Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence, Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia i Meditsinskoi Promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe Obshchestvo Nevrologov [i] Vserossiiskoe Obshchestvo Psikhiatrov, 115, 53, 10.17116/jnevro20151156153-62 · DOI
  17. Leggio, 2012, Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection, Addictive Behaviors, 37, 561, 10.1016/j.addbeh.2011.12.010 · DOI · Paper page
  18. Leggio, 2013, A human laboratory pilot study with baclofen in alcoholic individuals, Pharmacology, Biochemistry, and Behavior, 103, 784, 10.1016/j.pbb.2012.11.013 · DOI · Paper page
  19. Morley, 2013, The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial, Contemporary Clinical Trials, 36, 348, 10.1016/j.cct.2013.08.002 · DOI
  20. Müller, 2015, High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial, European Neuropsychopharmacology, 25, 1167, 10.1016/j.euroneuro.2015.04.002 · DOI · Paper page
  21. Pommier, 2014, Severity of deliberate acute baclofen poisoning: a nonconcurrent cohort study, Basic & Clinical Pharmacology & Toxicology, 114, 360, 10.1111/bcpt.12161 · DOI
  22. Ponizovsky, 2015, Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up, Journal of Substance Abuse Treatment, 52, 24, 10.1016/j.jsat.2014.11.007 · DOI
  23. Rigal, 2015, Tolerability of high-dose baclofen in the treatment of patients with alcohol disorders: a retrospective study, Alcohol and Alcoholism (Oxford, Oxfordshire), 50, 551, 10.1093/alcalc/agv052 · DOI
  24. Rolland, 2017, Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol, Expert Opinion on Drug Safety, 16, 125
  25. Simioni, 2016, Characteristics of patients with alcohol dependence seeking baclofen treatment in France: a two-centre comparative cohort study, Alcohol and Alcoholism (Oxford, Oxfordshire), 51, 664, 10.1093/alcalc/agw011 · doi:10.1093/alcalc/agw011
  26. Vourc'h, 2016, Baclofen to prevent agitation in alcohol-addicted patients in the ICU: study protocol for a randomised controlled trial, Trials, 17, 415, 10.1186/s13063-016-1539-2 · DOI
  27. Addolorato, 2002, Rapid suppression of alcohol withdrawal syndrome by baclofen, American Journal of Medicine, 112, 226, 10.1016/S0002-9343(01)01088-9 · DOI
  28. Addolorato, 2003, Suppression of alcohol delirium tremens by baclofen administration: a case report, Clinical Neuropharmacology, 26, 258, 10.1097/00002826-200309000-00010 · DOI · Paper page
  29. Amato, 2011, Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008537.pub2 · DOI · Paper page
  30. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders
  31. Bowery, 1987, GABAA and GABAB receptor site distribution in the rat central nervous system, Neuroscience, 20, 365, 10.1016/0306-4522(87)90098-4 · DOI · Paper page
  32. Carter, 2009, Behavioral analyses of GHB: receptor mechanisms, Pharmacology & Therapeutics, 121, 100, 10.1016/j.pharmthera.2008.10.003 · DOI · Paper page
  33. Colombo, 2000, Ability of baclofen in reducing alcohol intake and withdrawal severity: I - preclinical evidence, Alcoholism, Clinical and Experimental Research, 24, 58
  34. Davidoff, 1985, Antispasticity drugs: mechanisms of action, Annals of Neurology, 17, 107, 10.1002/ana.410170202 · DOI · Paper page
  35. Dissanaike, 2006, An ethanol protocol to prevent alcohol withdrawal syndrome, Journal of the American College of Surgeons, 203, 186, 10.1016/j.jamcollsurg.2006.04.025 · DOI
  36. Dodd, 2000, Glutamate-mediated transmission, alcohol, and alcoholism, Neurochemistry International, 37, 509, 10.1016/S0197-0186(00)00061-9 · DOI · Paper page
  37. Fiellin, 2002, Risk for delirium tremens in patients with alcohol withdrawal syndrome, Substance Abuse, 23, 83, 10.1080/08897070209511478 · DOI · Paper page
  38. Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org
  39. Knapp, 2007, Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal, Alcoholism, Clinical and Experimental Research, 31, 582, 10.1111/j.1530-0277.2007.00342.x · DOI
  40. Leggio, 2008, New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications, Biological Psychiatry, 32, 1106
  41. Lejoyeux, 1998, Benzodiazepine treatment for alcohol-dependent patients, Alcohol and Alcoholism (Oxford, Oxfordshire), 33, 563, 10.1093/alcalc/33.6.563 · DOI · Paper page
  42. Lerner, 1985, The alcohol withdrawal syndrome, New England Journal of Medicine, 313, 951, 10.1056/NEJM198510103131509 · DOI
  43. Liang, 2004, Altered pharmacology of synaptic and extrasynaptic GABAA receptors on CA1 hippocampal neurons is consistent with subunit changes in a model of alcohol withdrawal and dependence, Journal of Pharmacology and Experimental Therapeutics, 310, 1234, 10.1124/jpet.104.067983 · DOI
  44. McDonald, 2008, Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats, Psychopharmacology, 197, 591, 10.1007/s00213-008-1077-z · DOI
  45. Minozzi, 2010, Anticonvulsants for alcohol withdrawal, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005064.pub3 · DOI · Paper page
  46. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014
  47. Stallings, 2007, Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review, Journal of Oklahoma State Medical Association, 100, 354
  48. Weiss, 2002, Behavioral neurobiology of alcohol addiction: recent advances and challenges, Journal of Neuroscience, 22, 3332, 10.1523/JNEUROSCI.22-09-03332.2002 · DOI · Paper page
  49. Westerink, 1996, The pharmacology of mesolimbic dopamine neurons: a dual-probe micro dialysis study in the ventral tegmental area and nucleus accumbens of the rat brain, Journal of Neuroscience, 16, 2605, 10.1523/JNEUROSCI.16-08-02605.1996 · DOI · Paper page
  50. Liu, 2010, Baclofen for alcohol withdrawal, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008502 · DOI
  51. Liu, 2011, Baclofen for alcohol withdrawal, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008502.pub2 · DOI
  52. Liu, 2013, Baclofen for alcohol withdrawal, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008502.pub3 · DOI

Cited by

See all 102

Metadata

Authors
Liu, J., & Wang, L.-N.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2017-08-20
Volume
2019
Issue
11
Pages
CD008502-CD008502
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1589454228
Cited by
102
References
7
FWCI
6.35
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.